Last reviewed · How we verify
wIPV-bOPV-bOPV vaccination schedule
This vaccine induces immunity against poliovirus types 1, 2, and 3.
This vaccine induces immunity against poliovirus types 1, 2, and 3. Used for Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3.
At a glance
| Generic name | wIPV-bOPV-bOPV vaccination schedule |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine works by stimulating the body's immune system to produce antibodies and immune cells that can recognize and neutralize poliovirus particles. This leads to long-term immunity against polio, preventing the virus from causing disease.
Approved indications
- Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in Infants (PHASE3)
- A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- wIPV-bOPV-bOPV vaccination schedule CI brief — competitive landscape report
- wIPV-bOPV-bOPV vaccination schedule updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI